Filing Flows › TG Therapeutics (TGTX) › Q2 2026 › vs Q1 2026
TG Therapeutics (TGTX) Q2 2026 vs Q1 2026 (quarter over quarter)
TG Therapeutics's revenue rose $35.4M (+17%) from $205M in Q1 2026 to $240M in Q2 2026. The biggest changes: Product +$34.5M (+17%); License +$931K (+26%). Operating margin 9.0% against 17.0% (-8.0 pts).
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 9.0% | 17.0% | -8.0 pts |
| Net margin | 3.2% | 9.7% | -6.4 pts |
| Free cash flow margin | 16.2% | -8.8% | +25.0 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $236M | $201M | $34.5M | +17% |
| License | $4.5M | $3.6M | $931K | +26% |
| Revenue | $240M | $205M | $35.4M | +17% |
| Operating profit | $21.7M | $34.8M | −$13.1M | -38% |
| Costs & expenses | $219M | $170M | $48.5M | +29% |
| Pre-tax earnings | $10.2M | $20.4M | −$10.1M | -50% |
| Other expense, net | $11.4M | $14.4M | −$3.0M | -21% |
| Cost of revenue | $41.2M | $33.5M | $7.7M | +23% |
| Research & development | $95.3M | $48.4M | $46.9M | +97% |
| SG&A | $82.1M | $88.2M | −$6.1M | -7% |
| Net earnings | $7.8M | $19.8M | −$12.0M | -61% |
| Income tax | $2.5M | $586K | $1.9M | +319% |
| Depreciation & amortization | $53K | $32K | $21K | +66% |
| Share-based compensation | $27.9M | $19.9M | $7.9M | +40% |
| Working capital & other | $3.6M | −$57.7M | $61.2M | — |
| Operating cash flow | $39.3M | −$17.9M | $57.2M | — |
| Free cash flow (OCF − capex) | $39.0M | −$17.9M | $56.9M | — |
| Capital expenditures | $293K | $51K | $242K | +475% |
Questions
How much did TG Therapeutics's revenue grow quarter over quarter in Q2 2026?
TG Therapeutics's revenue rose $35.4M (+17%) from $205M in Q1 2026 to $240M in Q2 2026.
What drove TG Therapeutics's revenue change in Q2 2026?
Product +$34.5M (+17%); License +$931K (+26%).